Cargando…
Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C
Patients with chronic hepatitis C virus (HCV) develop hepatocellular carcinoma (HCC) regardless of achieving a sustained viral response (SVR). Because advanced liver fibrosis is a powerful risk factor for HCC, we analyzed the association between autotaxin (ATX), a liver fibrosis marker, and post-SVR...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350226/ https://www.ncbi.nlm.nih.gov/pubmed/32630450 http://dx.doi.org/10.3390/ijms21124517 |
_version_ | 1783557222159089664 |
---|---|
author | Takemura, Kazuya Takizawa, Etsuko Tamori, Akihiro Nakamae, Mika Kubota, Hiroshi Uchida-Kobayashi, Sawako Enomoto, Masaru Kawada, Norifumi Hino, Masayuki |
author_facet | Takemura, Kazuya Takizawa, Etsuko Tamori, Akihiro Nakamae, Mika Kubota, Hiroshi Uchida-Kobayashi, Sawako Enomoto, Masaru Kawada, Norifumi Hino, Masayuki |
author_sort | Takemura, Kazuya |
collection | PubMed |
description | Patients with chronic hepatitis C virus (HCV) develop hepatocellular carcinoma (HCC) regardless of achieving a sustained viral response (SVR). Because advanced liver fibrosis is a powerful risk factor for HCC, we analyzed the association between autotaxin (ATX), a liver fibrosis marker, and post-SVR HCC development within 3 years after antiviral treatment. We included 670 patients with HCV who received direct-acting antivirals, achieved SVR and were followed up for at least 6 months (270 of them were followed up for 3 years or more). We measured serum ATX levels before treatment and 12/24 weeks after treatment. The diagnosis of HCC was based on imaging modalities, such as dynamic computed tomography and dynamic magnetic resonance imaging and/or liver biopsy. The present study revealed that high levels of serum ATX predicted post-SVR HCC development (area under the receiver operating characteristic: 0.70–0.76). However, Wisteria floribunda agglutinin positive Mac-2 binding protein (M2BPGi), another liver fibrosis marker, was a more useful predictive marker especially post-treatment according to a multivariate analysis. Patients with a high rate of ATX reduction before and after antiviral treatment did not develop HCC regardless of high pretreatment ATX levels. In conclusion, post-treatment M2BPGi level and the combination of pretreatment ATX levels and rate of ATX reduction were useful predictive markers for post-SVR HCC development in patients with chronic HCV infection. |
format | Online Article Text |
id | pubmed-7350226 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-73502262020-07-15 Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C Takemura, Kazuya Takizawa, Etsuko Tamori, Akihiro Nakamae, Mika Kubota, Hiroshi Uchida-Kobayashi, Sawako Enomoto, Masaru Kawada, Norifumi Hino, Masayuki Int J Mol Sci Article Patients with chronic hepatitis C virus (HCV) develop hepatocellular carcinoma (HCC) regardless of achieving a sustained viral response (SVR). Because advanced liver fibrosis is a powerful risk factor for HCC, we analyzed the association between autotaxin (ATX), a liver fibrosis marker, and post-SVR HCC development within 3 years after antiviral treatment. We included 670 patients with HCV who received direct-acting antivirals, achieved SVR and were followed up for at least 6 months (270 of them were followed up for 3 years or more). We measured serum ATX levels before treatment and 12/24 weeks after treatment. The diagnosis of HCC was based on imaging modalities, such as dynamic computed tomography and dynamic magnetic resonance imaging and/or liver biopsy. The present study revealed that high levels of serum ATX predicted post-SVR HCC development (area under the receiver operating characteristic: 0.70–0.76). However, Wisteria floribunda agglutinin positive Mac-2 binding protein (M2BPGi), another liver fibrosis marker, was a more useful predictive marker especially post-treatment according to a multivariate analysis. Patients with a high rate of ATX reduction before and after antiviral treatment did not develop HCC regardless of high pretreatment ATX levels. In conclusion, post-treatment M2BPGi level and the combination of pretreatment ATX levels and rate of ATX reduction were useful predictive markers for post-SVR HCC development in patients with chronic HCV infection. MDPI 2020-06-25 /pmc/articles/PMC7350226/ /pubmed/32630450 http://dx.doi.org/10.3390/ijms21124517 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Takemura, Kazuya Takizawa, Etsuko Tamori, Akihiro Nakamae, Mika Kubota, Hiroshi Uchida-Kobayashi, Sawako Enomoto, Masaru Kawada, Norifumi Hino, Masayuki Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C |
title | Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C |
title_full | Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C |
title_fullStr | Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C |
title_full_unstemmed | Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C |
title_short | Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C |
title_sort | post-treatment m2bpgi level and the rate of autotaxin reduction are predictive of hepatocellular carcinoma development after antiviral therapy in patients with chronic hepatitis c |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350226/ https://www.ncbi.nlm.nih.gov/pubmed/32630450 http://dx.doi.org/10.3390/ijms21124517 |
work_keys_str_mv | AT takemurakazuya posttreatmentm2bpgilevelandtherateofautotaxinreductionarepredictiveofhepatocellularcarcinomadevelopmentafterantiviraltherapyinpatientswithchronichepatitisc AT takizawaetsuko posttreatmentm2bpgilevelandtherateofautotaxinreductionarepredictiveofhepatocellularcarcinomadevelopmentafterantiviraltherapyinpatientswithchronichepatitisc AT tamoriakihiro posttreatmentm2bpgilevelandtherateofautotaxinreductionarepredictiveofhepatocellularcarcinomadevelopmentafterantiviraltherapyinpatientswithchronichepatitisc AT nakamaemika posttreatmentm2bpgilevelandtherateofautotaxinreductionarepredictiveofhepatocellularcarcinomadevelopmentafterantiviraltherapyinpatientswithchronichepatitisc AT kubotahiroshi posttreatmentm2bpgilevelandtherateofautotaxinreductionarepredictiveofhepatocellularcarcinomadevelopmentafterantiviraltherapyinpatientswithchronichepatitisc AT uchidakobayashisawako posttreatmentm2bpgilevelandtherateofautotaxinreductionarepredictiveofhepatocellularcarcinomadevelopmentafterantiviraltherapyinpatientswithchronichepatitisc AT enomotomasaru posttreatmentm2bpgilevelandtherateofautotaxinreductionarepredictiveofhepatocellularcarcinomadevelopmentafterantiviraltherapyinpatientswithchronichepatitisc AT kawadanorifumi posttreatmentm2bpgilevelandtherateofautotaxinreductionarepredictiveofhepatocellularcarcinomadevelopmentafterantiviraltherapyinpatientswithchronichepatitisc AT hinomasayuki posttreatmentm2bpgilevelandtherateofautotaxinreductionarepredictiveofhepatocellularcarcinomadevelopmentafterantiviraltherapyinpatientswithchronichepatitisc |